SS-31 Peptide Dosage Protocol: What Is Known, What Is Not, and Safety Notes

SS-31, also called elamipretide, is a mitochondria-targeted peptide studied for cardiolipin stabilization and mitochondrial function. There is no universal SS-31 “dosage protocol” for longevity or wellness, and SS-31 is not FDA-approved for that use. Dosing depends on the studied condition, formulation, route, and clinician oversight; online research protocols should not be treated as medical instructions.

What is SS-31 peptide, and why do people search for a dosage protocol?

SS-31 is a small synthetic peptide, also called elamipretide, MTP-131, and Bendavia in some development settings. People search for a “dosage protocol” because SS-31 is discussed online as a mitochondrial and longevity peptide, but that is not the same as having a proven wellness dosing plan.

SS-31 is described as a mitochondria-targeted tetrapeptide. A tetrapeptide has four amino-acid building blocks. Its main proposed target is cardiolipin, a fat-like molecule that helps organize the inner mitochondrial membrane, where cells make much of their usable energy as ATP 1.

The key patient point is simple: a research compound may have a real biological mechanism and still lack an evidence-based protocol for longevity. For longevity use, SS-31 remains investigational; mechanism alone does not prove better energy, slower aging, or longer life in people 1, 6.

What are the key facts about SS-31?

Elamipretide is the generic name most often used in clinical research. SS-31, MTP-131, and Bendavia are names you may see in older papers, trial materials, or online peptide content.

• Generic name: elamipretide.
• Other names: SS-31, MTP-131, and Bendavia in some development contexts.
• Drug class: mitochondria-targeted peptide.
• Structure: synthetic tetrapeptide.
• Main proposed target: cardiolipin in the inner mitochondrial membrane 1.
• Main research idea: support mitochondrial structure and function under stress, not act as a broad antioxidant 1.
• Longevity use: investigational, not established as an anti-aging treatment.
• Chia availability: Chia does not currently offer SS-31.

Is there an evidence-based SS-31 dosage protocol for longevity?

No. There is no evidence-based SS-31 dosage protocol for longevity that can be recommended to the general public. Published doses come from specific research settings, not from approved anti-aging or wellness guidelines.

This distinction matters. In clinical trials, investigators define the condition, route, formulation, eligibility rules, lab monitoring, stopping rules, and adverse-event tracking before any dose is given. An online “SS-31 protocol” usually lacks that safety structure.

For example, elamipretide has been studied in people with primary mitochondrial myopathy and Barth syndrome, and in cardiovascular research settings 3, 4, 5. Those studies can teach us about safety signals and disease-specific outcomes, but they do not create a general wellness dose.

What dosage information can and cannot be taken from research studies?

Research dosing can show what investigators tested in a controlled setting. It cannot tell an individual reader what to use, whether to use it, or how to combine it with other peptides or medications.

Why animal doses do not translate directly to human doses

Animal studies can be useful because they let researchers test injury models that cannot be created in people. In kidney ischemia-reperfusion injury models, SS-31 has been investigated for mitochondrial injury and oxidative-stress-related damage 2.

But the dose in a mouse or rat study reflects the animal species, disease model, route, timing, and lab endpoint. It is not a human dose. Converting animal doses into a patient protocol is unsafe without formal clinical development and clinician oversight.

Why cell and drug-delivery studies cannot define patient dosing

Cell studies help explain where SS-31 goes and how it may interact with mitochondria. A review of SS-31-based mitochondrial targeting describes its use in experimental drug-delivery systems, but those studies do not prove human benefit for longevity 1.

Cells in a dish do not have a liver, kidneys, immune system, blood flow, injection-site tissue, or medication interactions. That is why cell work cannot define a safe patient dose.

Why clinical-trial dosing is not the same as a wellness protocol

Clinical-trial dosing is disease-specific. In one heart-attack reperfusion study, elamipretide was tested during primary percutaneous coronary intervention, and the study did not show a reduction in infarct size as the main clinical goal 5. That finding should not be generalized into an anti-aging claim.

Trials in primary mitochondrial myopathy and Barth syndrome studied defined patient groups with rare or specific conditions 3, 4. Even when a trial suggests a signal in one group, it does not prove benefit for healthy adults seeking energy, recovery, or lifespan extension.

How is SS-31 thought to work in mitochondria?

SS-31’s main proposed mechanism is mitochondrial targeting through cardiolipin. Cardiolipin helps hold key energy-producing proteins in the right shape and place inside the inner mitochondrial membrane 1.

Cardiolipin and the inner mitochondrial membrane

Mitochondria are often called the cell’s energy centers. The inner mitochondrial membrane is folded and packed with protein complexes that help move electrons and make ATP, the energy currency cells use.

Cardiolipin is a special lipid in that membrane. It helps organize the electron transport chain and supports the function of proteins such as cytochrome c, which helps move electrons during energy production 1, 7.

Electron transport, ATP production, and reactive oxygen species

When mitochondria are stressed, electron flow can become less efficient. That may lower ATP production and increase reactive oxygen species, also called ROS. ROS are not always bad; they also act as cell signals. Problems can arise when oxidative stress overwhelms normal defenses 7.

SS-31 is studied because it may help stabilize cardiolipin and support electron-transport function under stress 1. This is a plausible mechanism, but it is still not the same as a proven longevity outcome.

Why mechanism does not prove clinical benefit

Many compounds look promising at the mechanism stage and then show mixed results in human trials. Elamipretide is a good example: it has strong mitochondrial logic, but human outcomes have varied by disease and study design 3, 5.

For patients, the practical lesson is to separate “how it might work” from “what it has been shown to do in people.” The first is biology. The second requires human trials.

What does the research say about SS-31 benefits?

Elamipretide research is interesting, but it is not proof of broad wellness benefit. Human studies are limited to specific diseases, while animal and cell studies are hypothesis-generating.

Human evidence: limited to specific disease research and should not be generalized

In primary mitochondrial myopathy, elamipretide has been tested because mitochondrial dysfunction is central to the disease. The MMPOWER-3 trial studied daily subcutaneous elamipretide in people with primary mitochondrial myopathy, but the published trial did not meet its primary endpoints 3.

In Barth syndrome, a rare genetic condition involving cardiolipin remodeling, elamipretide has been studied because the disease is closely tied to mitochondrial membrane biology 4. Those findings are disease-specific and should not be stretched into a general anti-aging claim.

In heart-attack reperfusion research, Bendavia, another development name for elamipretide, was tested during treatment for ST-elevation myocardial infarction. The EMBRACE STEMI study did not show the hoped-for reduction in infarct size 5.

Animal evidence: kidney injury and mitochondrial-stress models

Animal kidney studies suggest SS-31 may reduce mitochondrial injury, oxidative stress, and tissue damage in experimental acute kidney injury models 2. This is useful preclinical science.

It is not proof that SS-31 improves kidney function in people, prevents kidney injury, or provides an anti-aging benefit. Animal results often fail to translate fully to humans because human disease is more complex.

Cell and delivery evidence: mitochondrial targeting and experimental drug-delivery uses

SS-31 has also been studied as a mitochondrial-targeting tool in drug-delivery research 1. This line of work is important because getting compounds into mitochondria is hard.

But drug-delivery studies are not the same as clinical outcomes. They help explain delivery and mechanism, not whether a person will feel more energy, recover faster, or live longer.

Longevity evidence: hypothesis-generating, not proof of longer lifespan in humans

The longevity interest comes from a reasonable idea: mitochondrial dysfunction is linked with aging biology, and SS-31 targets mitochondrial structure and stress pathways 1, 6. That makes it scientifically interesting.

Still, there is no strong human evidence that SS-31 extends lifespan or works as an anti-aging treatment. If you see a protocol promising energy, recovery, or longevity results, treat that as a claim that needs proof.

What are the safety concerns with SS-31 protocols found online?

Online SS-31 protocols can be risky because they often skip the parts that make medical treatment safer: diagnosis, product quality, sterile handling, interaction review, follow-up, and adverse-event monitoring.

Unknown product quality and sterility risks

Many online peptide products are sold as “research use” items, not patient prescriptions. That can leave major questions about identity, potency, sterility, storage, and contamination.

The safer axis is licensed versus unlicensed: a licensed clinician and a state-licensed pharmacy have rules, records, and accountability. A no-prescription research-chemical vendor may not.

Injection and reconstitution risks

Some SS-31 protocols online discuss injections and vial reconstitution. Those steps can introduce infection, dosing error, contamination, or tissue injury if handled incorrectly.

This is one reason we do not turn research-use vial examples into patient instructions. Route, concentration, volume, sterility, and storage all matter.

Side effects, interactions, and monitoring gaps

Human studies of elamipretide have tracked adverse events under protocol rules, but trial safety monitoring is not the same as self-use 3, 4. A person’s risks may change with kidney disease, heart disease, pregnancy status, immune conditions, or other medications.

Any claimed benefit should be weighed against possible side effects, unknown interactions, and the chance that symptoms such as fatigue have another cause that needs medical care.

Why a licensed clinician matters

A clinician can ask the questions a dose chart cannot: Why are you considering this? What diagnosis is being treated? What medications do you take? What labs or follow-up are needed? What would make treatment unsafe?

That is the standard we use at Chia for treatments we do offer: a 100% online health questionnaire, licensed US provider review, prescribing only when clinically appropriate, provider-guided dosing, and pharmacy dispensing through state-licensed 503A compounding pharmacies.

Does Chia offer SS-31 peptide?

No. Chia does not currently prescribe or sell SS-31, elamipretide, MTP-131, or Bendavia. This article is education-only so patients can understand the research limits and safety issues.

Chia’s available longevity-related treatments include NAD+, glutathione, sermorelin, and GHK-Cu Cream. We also offer multi-treatment options such as Foundation Longevity, which includes sermorelin injection, NAD+ injection, and glutathione injection.

These are not substitutes for SS-31. They have different mechanisms, different evidence limits, and different safety questions. If you start with Chia, a prescription requires a medical evaluation and is not guaranteed. Compounded medications are not FDA-approved.

How should patients evaluate any peptide dosage protocol?

A safe review starts with one question: is this a medical treatment plan or just an online protocol? A peptide dosage protocol should be judged by evidence, route, product source, monitoring, and clinician oversight.

1. 1Check whether the use is FDA-approved, off-label, or investigational. Longevity, fatigue, and performance claims need direct human evidence.
2. 2Confirm whether the product comes from a licensed pharmacy, not a no-prescription research-chemical source.
3. 3Ask what evidence supports the dose, route, duration, and stopping rules. A cell study or animal study cannot answer those patient questions.
4. 4Review your medical history, medications, allergies, pregnancy status, kidney and liver health, and heart history with a clinician.
5. 5Ask what side effects to watch for and what follow-up, labs, or symptom checks are needed.
6. 6Be careful with stacks. Combining peptides can add uncertainty because many combinations have not been tested together in human trials.

If you are interested in Chia treatments that we do offer, you can start with our online eligibility quiz at /quiz. For SS-31 specifically, Chia does not currently offer it, and we do not route patients to an SS-31 prescription.

FAQ

Keep reading

Peptides

SS-31 Peptide: What to Know Before You Buy

Peptides

SS-31 Peptide Dose Per Day: What Research Can and Cannot Tell You

Peptides

SS-31 Peptide (Elamipretide): What It Is, How It Works, and What the Evidence Shows